Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Diseases

  Free Subscription


Articles published in J Gastroenterol

Retrieve available abstracts of 70 articles:
HTML format
Text format



Single Articles


    May 2018
  1. ENOOKU K, Kondo M, Fujiwara N, Sasako T, et al
    Hepatic IRS1 and ss-catenin expression is associated with histological progression and overt diabetes emergence in NAFLD patients.
    J Gastroenterol. 2018 May 10. pii: 10.1007/s00535-018-1472.
    PubMed     Text format     Abstract available


  2. ORIMO T, Kamiyama T, Mitsuhashi T, Kamachi H, et al
    Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2018 May 2. pii: 10.1007/s00535-018-1469.
    PubMed     Text format     Abstract available


    April 2018
  3. KAKISAKA K, Suzuki Y, Fujiwara Y, Abe T, et al
    Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    J Gastroenterol. 2018 Apr 21. pii: 10.1007/s00535-018-1468.
    PubMed     Text format     Abstract available


    December 2017
  4. SHINKAI N, Nojima M, Iio E, Matsunami K, et al
    High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues.
    J Gastroenterol. 2017 Dec 29. pii: 10.1007/s00535-017-1424.
    PubMed     Text format     Abstract available


    November 2017
  5. SUZUKI Y, Mori T, Yokoyama M, Kim S, et al
    A proposed severity classification system for hepatolithiasis based on an analysis of prognostic factors in a Japanese patient cohort.
    J Gastroenterol. 2017 Nov 8. doi: 10.1007/s00535-017-1410.
    PubMed     Text format     Abstract available


  6. SHANG L, Hosseini M, Liu X, Kisseleva T, et al
    Human hepatic stellate cell isolation and characterization.
    J Gastroenterol. 2017 Nov 1. doi: 10.1007/s00535-017-1404.
    PubMed     Text format     Abstract available


    October 2017
  7. KOYAMA N, Yamazaki T, Kanetsuki Y, Hirota J, et al
    Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 30. doi: 10.1007/s00535-017-1398.
    PubMed     Text format     Abstract available


  8. NAKAO M, Nakayama N, Uchida Y, Tomiya T, et al
    Nationwide survey for acute liver failure and late-onset hepatic failure in Japan.
    J Gastroenterol. 2017 Oct 13. doi: 10.1007/s00535-017-1394.
    PubMed     Text format     Abstract available


  9. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Erratum to: Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2017 Oct 11. doi: 10.1007/s00535-017-1392.
    PubMed     Text format     Abstract available


    September 2017
  10. CHAYAMA K, Suzuki F, Karino Y, Kawakami Y, et al
    Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
    J Gastroenterol. 2017 Sep 25. doi: 10.1007/s00535-017-1391.
    PubMed     Text format     Abstract available


  11. IMPERATORE N, Tortora R, Testa A, Gerbino N, et al
    Erratum to: Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Sep 19. doi: 10.1007/s00535-017-1393.
    PubMed     Text format     Abstract available


    August 2017
  12. KAWAGUCHI K, Honda M, Ohta H, Terashima T, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts hepatocellular carcinoma incidence and recurrence in nucleos(t)ide analogue therapy for chronic hepatitis B.
    J Gastroenterol. 2017 Aug 28. doi: 10.1007/s00535-017-1386.
    PubMed     Text format     Abstract available


  13. IMPERATORE N, Tortora R, Anna T, Gerbino N, et al
    Proton pump inhibitors as risk factor for metabolic syndrome and hepatic steatosis in coeliac disease patients on gluten-free diet.
    J Gastroenterol. 2017 Aug 19. doi: 10.1007/s00535-017-1381.
    PubMed     Text format     Abstract available


  14. KOBAYASHI K, Maruyama H, Kiyono S, Ogasawara S, et al
    Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis.
    J Gastroenterol. 2017 Aug 18. doi: 10.1007/s00535-017-1378.
    PubMed     Text format     Abstract available


  15. SHIDA T, Akiyama K, Oh S, Sawai A, et al
    Skeletal muscle mass to visceral fat area ratio is an important determinant affecting hepatic conditions of non-alcoholic fatty liver disease.
    J Gastroenterol. 2017 Aug 8. doi: 10.1007/s00535-017-1377.
    PubMed     Text format     Abstract available


  16. IKEDA M, Kudo M, Aikata H, Nagamatsu H, et al
    Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial.
    J Gastroenterol. 2017 Aug 1. doi: 10.1007/s00535-017-1374.
    PubMed     Text format     Abstract available


    July 2017
  17. KITAJIMA Y, Takahashi H, Akiyama T, Murayama K, et al
    Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis.
    J Gastroenterol. 2017 Jul 24. doi: 10.1007/s00535-017-1370.
    PubMed     Text format     Abstract available


  18. SEKO Y, Sumida Y, Sasaki K, Itoh Y, et al
    Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
    J Gastroenterol. 2017 Jul 1. doi: 10.1007/s00535-017-1364.
    PubMed     Text format     Abstract available


    June 2017
  19. HIRAMINE Y, Uojima H, Nakanishi H, Hiramatsu A, et al
    Response criteria of tolvaptan for the treatment of hepatic edema.
    J Gastroenterol. 2017 Jun 29. doi: 10.1007/s00535-017-1366.
    PubMed     Text format     Abstract available


  20. OKANOUE T, Ebise H, Kai T, Mizuno M, et al
    A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    J Gastroenterol. 2017 Jun 6. doi: 10.1007/s00535-017-1355.
    PubMed     Text format     Abstract available


  21. TAJIRI K, Kawai K, Sugiyama T
    Strain elastography for assessment of liver fibrosis and prognosis in patients with chronic liver diseases.
    J Gastroenterol. 2017;52:724-733.
    PubMed     Text format     Abstract available


    May 2017
  22. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Erratum to: Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 29. doi: 10.1007/s00535-017-1352.
    PubMed     Text format    


  23. MASUDA K, Ono A, Aikata H, Kawaoka T, et al
    Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy.
    J Gastroenterol. 2017 May 4. doi: 10.1007/s00535-017-1348.
    PubMed     Text format     Abstract available


    April 2017
  24. FLOREANI A, Tanaka A, Bowlus C, Gershwin ME, et al
    Geoepidemiology and changing mortality in primary biliary cholangitis.
    J Gastroenterol. 2017 Apr 1. doi: 10.1007/s00535-017-1333.
    PubMed     Text format     Abstract available


    March 2017
  25. CAI X, Hayashi S, Fang C, Hao S, et al
    Pu'erh tea extract-mediated protection against hepatosteatosis and insulin resistance in mice with diet-induced obesity is associated with the induction of de novo lipogenesis in visceral adipose tissue.
    J Gastroenterol. 2017 Mar 31. doi: 10.1007/s00535-017-1332.
    PubMed     Text format     Abstract available


  26. ZHANG AY, Lai CL, Huang FY, Seto WK, et al
    Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.
    J Gastroenterol. 2017 Mar 28. doi: 10.1007/s00535-017-1334.
    PubMed     Text format     Abstract available


  27. KISHIDA Y, Okubo H, Ohno H, Oki K, et al
    Effect of miglitol on the suppression of nonalcoholic steatohepatitis development and improvement of the gut environment in a rodent model.
    J Gastroenterol. 2017 Mar 27. doi: 10.1007/s00535-017-1331.
    PubMed     Text format     Abstract available


  28. HASEBE T, Tanaka H, Sawada K, Nakajima S, et al
    Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.
    J Gastroenterol. 2017;52:341-351.
    PubMed     Text format     Abstract available


    February 2017
  29. SETO WK, Yuen MF
    Nonalcoholic fatty liver disease in Asia: emerging perspectives.
    J Gastroenterol. 2017;52:164-174.
    PubMed     Text format     Abstract available


  30. MORIO R, Hyogo H, Hatooka M, Morio K, et al
    The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    J Gastroenterol. 2017;52:253-262.
    PubMed     Text format     Abstract available


  31. MIYAKE T, Hirooka M, Yoshida O, Furukawa S, et al
    Differences in the risk of fatty liver for onset of impaired fasting glucose according to baseline plasma glucose levels.
    J Gastroenterol. 2017;52:237-244.
    PubMed     Text format     Abstract available


    January 2017
  32. UTSUNOMIYA H, Yamamoto Y, Takeshita E, Tokumoto Y, et al
    Upregulated absorption of dietary palmitic acids with changes in intestinal transporters in non-alcoholic steatohepatitis (NASH).
    J Gastroenterol. 2017 Jan 6. doi: 10.1007/s00535-016-1298.
    PubMed     Text format     Abstract available


  33. NISHIO T, Taura K, Iwaisako K, Koyama Y, et al
    Hepatic vagus nerve regulates Kupffer cell activation via alpha7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis.
    J Gastroenterol. 2017 Jan 2. doi: 10.1007/s00535-016-1304.
    PubMed     Text format     Abstract available


    December 2016
  34. WANG W, Pan Q, Fuhler GM, Smits R, et al
    Action and function of Wnt/beta-catenin signaling in the progression from chronic hepatitis C to hepatocellular carcinoma.
    J Gastroenterol. 2016 Dec 29. doi: 10.1007/s00535-016-1299.
    PubMed     Text format     Abstract available


  35. OGAWA E, Furusyo N, Nomura H, Dohmen K, et al
    NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    November 2016
  36. SETOYAMA H, Tanaka M, Nagumo K, Naoe H, et al
    Oral branched-chain amino acid granules improve structure and function of human serum albumin in cirrhotic patients.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  37. TAKEDA H, Takai A, Inuzuka T, Marusawa H, et al
    Genetic basis of hepatitis virus-associated hepatocellular carcinoma: linkage between infection, inflammation, and tumorigenesis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  38. IKEDA K, Kudo M, Kawazoe S, Osaki Y, et al
    Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    September 2016
  39. TERAI S, Tsuchiya A
    Status of and candidates for cell therapy in liver cirrhosis: overcoming the "point of no return" in advanced liver cirrhosis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  40. KUSAMA H, Kon K, Ikejima K, Arai K, et al
    Sodium 4-phenylbutyric acid prevents murine acetaminophen hepatotoxicity by minimizing endoplasmic reticulum stress.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  41. KUDO M, Hatano E, Ohkawa S, Fujii H, et al
    Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  42. KIYONO S, Maruyama H, Kondo T, Sekimoto T, et al
    Erratum to: Hemodynamic effect of the left gastric artery on esophageal varices in patients with cirrhosis.
    J Gastroenterol. 2016.
    PubMed     Text format    


  43. FURUICHI Y, Gotoda T, Moriyasu F, Ogawa S, et al
    Dual red imaging (novel advanced endoscopy) can increase visibility and can predict the depth in diagnosing esophageal varices.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    July 2016
  44. SAKAIDA I, Terai S, Nakajima K, Shibasaki Y, et al
    Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    June 2016
  45. SHODA J, Matsuda A, Shida T, Yamamoto M, et al
    Wisteria floribunda agglutinin-sialylated mucin core polypeptide 1 is a sensitive biomarker for biliary tract carcinoma and intrahepatic cholangiocarcinoma: a multicenter study.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  46. YAMADA N, Sanada Y, Tashiro M, Hirata Y, et al
    Serum Mac-2 binding protein glycosylation isomer predicts grade F4 liver fibrosis in patients with biliary atresia.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  47. AOKI T, Iijima H, Tada T, Kumada T, et al
    Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  48. FUKUI H, Saito H, Ueno Y, Uto H, et al
    Evidence-based clinical practice guidelines for liver cirrhosis 2015.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  49. TANAKA A, Takikawa H, Mochida S, Koike K, et al
    Changing Nomenclature for PBC from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis".
    J Gastroenterol. 2016.
    PubMed     Text format    


  50. KUMAGAI E, Korenaga K, Korenaga M, Imamura M, et al
    Appropriate use of virtual touch quantification and FibroScan M and XL probes according to the skin capsular distance.
    J Gastroenterol. 2016;51:496-505.
    PubMed     Text format     Abstract available


    April 2016
  51. KUDO M, Ikeda M, Takayama T, Numata K, et al
    Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  52. SUGIYAMA A, Kanno K, Nishimichi N, Ohta S, et al
    Periostin promotes hepatic fibrosis in mice by modulating hepatic stellate cell activation via alpha integrin interaction.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  53. GREUTER T, Shah VH
    Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  54. KANEKO S, Ikeda K, Matsuzaki Y, Furuse J, et al
    Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  55. CAI X, Fang C, Hayashi S, Hao S, et al
    Pu-erh tea extract ameliorates high-fat diet-induced nonalcoholic steatohepatitis and insulin resistance by modulating hepatic IL-6/STAT3 signaling in mice.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  56. KIYONO S, Maruyama H, Kondo T, Sekimoto T, et al
    Hemodynamic effect of the left gastric artery on esophageal varices in patients with cirrhosis.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


  57. AKAHOSHI K, Tanaka S, Mogushi K, Shimada S, et al
    Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors.
    J Gastroenterol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  58. MARUYAMA H, Sekimoto T, Yokosuka O
    Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  59. NAKANISHI H, Kurosaki M, Hosokawa T, Takahashi Y, et al
    Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  60. YANG SL, Liu LP, Sun YF, Yang XR, et al
    Distinguished prognosis after hepatectomy of HBV-related hepatocellular carcinoma with or without cirrhosis: a long-term follow-up analysis.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


  61. OKUSHIN K, Tsutsumi T, Enooku K, Fujinaga H, et al
    The intrahepatic expression levels of bile acid transporters are inversely correlated with the histological progression of nonalcoholic fatty liver disease.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    September 2015
  62. DEGIORGIO D, Crosignani A, Colombo C, Bordo D, et al
    ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    May 2015
  63. MIYAKE T, Kumagi T, Furukawa S, Hirooka M, et al
    Short sleep duration reduces the risk of nonalcoholic fatty liver disease onset in men: a community-based longitudinal cohort study.
    J Gastroenterol. 2015;50:583-9.
    PubMed     Text format     Abstract available


    April 2015
  64. YAMAZAKI S, Takayama T, Higaki T, Moriguchi M, et al
    Pancrelipase with branched-chain amino acids for preventing nonalcoholic fatty liver disease after pancreaticoduodenectomy.
    J Gastroenterol. 2015.
    PubMed     Text format     Abstract available


    March 2015
  65. KAWAGUCHI T, Kohjima M, Ichikawa T, Seike M, et al
    The morbidity and associated risk factors of cancer in chronic liver disease patients with diabetes mellitus: a multicenter field survey.
    J Gastroenterol. 2015;50:333-41.
    PubMed     Text format     Abstract available


    January 2015
  66. SAKAI Y, Iwata Y, Enomoto H, Saito M, et al
    Two randomized controlled studies comparing the nutritional benefits of branched-chain amino acid (BCAA) granules and a BCAA-enriched nutrient mixture for patients with esophageal varices after endoscopic treatment.
    J Gastroenterol. 2015;50:109-18.
    PubMed     Text format     Abstract available


  67. NISHIOJI K, Sumida Y, Kamaguchi M, Mochizuki N, et al
    Prevalence of and risk factors for non-alcoholic fatty liver disease in a non-obese Japanese population, 2011-2012.
    J Gastroenterol. 2015;50:95-108.
    PubMed     Text format     Abstract available


  68. TADA T, Kumada T, Toyoda H, Ito T, et al
    Diagnostic accuracy for macroscopic classification of nodular hepatocellular carcinoma: comparison of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and angiography-assisted computed tomography.
    J Gastroenterol. 2015;50:85-94.
    PubMed     Text format     Abstract available


  69. UMEMOTO Y, Okano S, Matsumoto Y, Nakagawara H, et al
    Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.
    J Gastroenterol. 2015;50:65-75.
    PubMed     Text format     Abstract available


    December 2014
  70. TANAKA T, Li T, Urata Y, Goto S, et al
    Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma.
    J Gastroenterol. 2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: